secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2024-12-13T23:59:59+00:00
Accession:  0001193125-24-277937
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam Pharma prices $416.5M upsized public offering; net proceeds ~$452.6M
--------------------------------------------------------------------------------

- Pricing of 12,117,347 ordinary shares at $24.50/share and 4,882,653 pre-funded warrants at $24.4999/warrant.
- Offering upsized from initial $300M to $416.5M; underwriters exercised option to buy additional 2,550,000 shares.
- Net proceeds to company expected ~$452.6M after underwriting discounts and estimated offering expenses.
- Closing expected on or about December 13, 2024, subject to customary conditions.
- Joint book-running managers: Jefferies, Goldman Sachs, Leerink Partners, TD Cowen, Guggenheim Securities, William Blair.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000119312524277937/0001193125-24-277937-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000119312524277937/d916004d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-277937

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer